lol...25 patients and drug is yet to be approved..most of drugs fails in late stage. It is even harder to get FDA approval.
I see GILD $25 within few years.
How about the Upgrades from Analysts?
I remember when DNDN was trading at $45 a share, analysts upgraded to $85
Now DNDN is trading @4